Login to Your Account



Financings NEWS

Arsanis Inc., an infectious disease specialist developing a targeted monoclonal antibody to prevent Staphylococcus aureus pneumonia, has closed on a $45.5 million series D financing that will help it complete a phase II trial of candidate ASN-100.

LONDON – Synpromics Ltd has raised £5.2 million in a series B round to advance the development and commercialization of its synthetic promoter technology for controlling and directing gene expression.

SHANGHAI – Chinese vaccine developer Cansino Inc., of Tianjin, has received $65 million in a financing round led by Future Industry Investment Fund to hasten the development of its later-stage vaccines and get a new vaccine plant up-and-running.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: